Please use this identifier to cite or link to this item:
|Title:||Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery|
Valle Delgado, Juan José
Mayor Aparicio, Alfredo Gabriel
Sinden, Robert E.
Paz, José L. de
García Salcedo, José A.
Fernàndez Busquets, Xavier
|Abstract:||The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.|
|Note:||Reproducció del document publicat a: http://dx.doi.org/10.1016/j.nano.2016.09.010|
|It is part of:||Nanomedicine: Nanotechnology, Biology and Medicine, 2017, vol. 13, num. 2, p. 515-525|
|Appears in Collections:||Articles publicats en revistes (ISGlobal)|
Files in This Item:
|MarquesJ_Nanomedicine_2017.pdf||1.42 MB||Adobe PDF||View/Open|
This item is licensed under a Creative Commons License